--- title: "Advert for Collaborator in Biological Research for Topical Product to assist with Scalp Cooling during Chemotherapy" ocid: "ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425" markdown_url: "https://d3tenders.com/contract/ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425.md" json_url: "https://d3tenders.com/contract/ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425.json" source: "Contracts Finder" current_stage: "Tender" buyer: "PAXMAN COOLERS LIMITED" published: "2022-07-13" --- # Advert for Collaborator in Biological Research for Topical Product to assist with Scalp Cooling during Chemotherapy Buyer: PAXMAN COOLERS LIMITED Current stage: Tender OCID: ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425) [Download OCDS JSON](https://d3tenders.com/contract/ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425.json) ## Summary Paxman Coolers Limited is seeking a collaborator in biological research for a topical product designed to assist with scalp cooling during chemotherapy. The tender, titled "Advert for Collaborator in Biological Research for Topical Product to assist with Scalp Cooling during Chemotherapy", falls under the medical equipment and pharmaceuticals category. The current procurement stage is open for tender submissions, with a deadline for submissions set for 25th July 2022. The contract is anticipated to commence on 8th August 2022 and will last until 28th February 2023. The estimated value of the contract is £100,000, with a minimum value of £87,500 set to foster competitive bids. This tender presents substantial opportunities for businesses specializing in cell biology, skin research, and pharmaceutics, particularly those with expertise in formulating topical agents for targeted delivery of antioxidants to hair follicles. Small and medium-sized enterprises (SMEs) and voluntary, community, and social enterprises (VCSEs) are encouraged to participate in this procurement, leveraging their innovative capabilities to enhance the efficacy of scalp cooling treatments for chemotherapy patients. Engaging in this contract could lead to valuable partnerships in the healthcare sector, where the need for effective solutions to mitigate chemotherapy-induced hair loss is increasingly recognized. ## Notice Paxman is a medical technology company with an established leadership position in the Scalp Cooling sector. The Paxman Scalp Cooling System (PSCS) minimizes hair loss in connection with chemotherapy treatment. The product is distributed to over 60 markets internationally, including: France, Germany, The Netherlands, Switzerland, Sweden, Russia, Brazil, Mexico, Australia, and the U.S. Scalp cooling is an important treatment, which has a strong clinical support and is a fully established therapy in many countries throughout the world. Chemotherapy-induced alopecia is the most feared side effect of treatment in >75% of patients. Often patients feel this is the most traumatic side effect of their cancer treatment and not only can it lead to social isolation, but hair loss can affect self-image more than breast surgery. Eight percent of patients refuse chemotherapy or request a less efficacious treatment due to the prospect of hair loss. The company has extensive global experience - since 2003, more than 65 clinical studies have been conducted in more than 17 countries and includes the first-ever randomized clinical trial to evaluate modern scalp cooling, which took place at several Cancer Centers in the United States as part of the FDA (Food and Drug Administration) clearance process. As part of Paxman's investment in biological research, it has been discovered that chemotherapy drugs induce oxidative stress inside cells of the hair follicles which causes cell toxicity (and ultimately hair loss). Therefore, a novel patented combinatorial approach was designed to reduce cell toxicity at "sub-optimal" cooling temperatures and has the potential to dramatically enhance the efficacy of the Paxman scalp cooling device. This intervention combines cooling with treatment with a reactive oxygen species (ROS) inhibitor (antioxidant compound) delivered into cells to reduce oxidative stress (and these findings have been confirmed using whole follicles mini-organ cultures). Using in vitro models, the company have now established a panel of antioxidant compounds which has shown extremely good efficacy in minimising or preventing cytotoxicity in combination with cooling. Paxman now need the expertise to be able to target these antioxidant compounds to human hair follicles of the scalp. This will require expertise in pharmaceutics in order to prepare topical agents with appropriate formulations for delivery of these antioxidants to the hair follicles. The identified third-party organisation must have both the cell biology/skin research as well as pharmaceutics expertise and research capabilities in order to be in position to deliver the proposed project. ## Key Details | Field | Value | | --- | --- | | Publication source | Contracts Finder | | Latest notice | https://www.contractsfinder.service.gov.uk/Notice/9ef6fd49-0e3d-48b4-ad90-f75d0bf4e20f | | Notice type | Tender Notice | | Procurement type | Standard | | Procurement category | Services | | Procurement method | Open | | Procurement method details | Open procedure (below threshold) | | Tender suitability | SME, VCSE | | Awardee scale | Not specified | | All stages | Tender | ## Dates | Field | Value | | --- | --- | | Publication date | 13 Jul 2022 | | Submission deadline | 25 Jul 2022 | | Future notice date | Not specified | | Award date | Not specified | | Contract period | 7 Aug 2022 - 28 Feb 2023 | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £100,000 | | Lots value | Not specified | | Awards value | Not specified | | Contracts value | Not specified | ## Status | Field | Value | | --- | --- | | Tender status | Active | | Lots status | Not specified | | Awards status | Not specified | | Contracts status | Not specified | ## Buyer | Field | Value | | --- | --- | | Main buyer | PAXMAN COOLERS LIMITED | | Locality | HUDDERSFIELD | | Post town | Huddersfield | | Postcode | HD8 0LE | | Country | England | | ITL 1 | TLE Yorkshire and The Humber | | ITL 2 | TLE4 West Yorkshire | | ITL 3 | TLE44 Calderdale and Kirklees | | Local authority | Kirklees | | Electoral ward | Almondbury | | Westminster constituency | Huddersfield | | Delivery location | Not specified | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33000000 - Medical equipments, pharmaceuticals and personal care products ## Release History - 13 Jul 2022 at 13:25 - Tender - Tender Notice - https://www.contractsfinder.service.gov.uk/Notice/9ef6fd49-0e3d-48b4-ad90-f75d0bf4e20f ## Documents - https://www.contractsfinder.service.gov.uk/Notice/9ef6fd49-0e3d-48b4-ad90-f75d0bf4e20f 13th July 2022 - Opportunity notice on Contracts Finder - https://www.contractsfinder.service.gov.uk/Notice/Attachment/120ccac2-f346-4272-8cb5-66bef7603745 Project Plan - https://www.contractsfinder.service.gov.uk/Notice/Attachment/7aae2d94-6ad3-4fac-815b-e4535e931553 Response form ## Notice URLs - http://www.paxmanscalpcooling.com ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-b5fd17-58505d9c-3c1d-450e-9e47-ab8f17a6f425.json.